The first FDA-approved angiogenesis inhibitor was the vascular endothelial growth factor (VEGF)-targeting monoclonal antibody (Mab) bevacizumab (Avastin; Genentech Inc., San Francisco, 2003), which continues to be used today in combination therapies against metastatic colorectal cancer,[5]
non-small-cell lung cancer,[6] and metastatic breast cancer.